Skip to content
DataLookout
Menu

NCT06964087

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

StatusRecruiting
PhasePhase 2
SponsorOp-T LLC
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from May 31, 2026 to May 31, 2027 Show 5 more changesShow less
    • Eligibility criteria shortened, about 11 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Start date changed from estimate of Apr 10, 2026 to Apr 23, 2026
    • Secondary endpoints: details revised at 2 of 5 entries
    • Study description revised
  2. Notable Trial status: Active, Not Recruiting to Recruiting
    • Start date: May 27, 2025 to Apr 10, 2026
    • Study sites: 1 to 5
    • Primary completion date: May 19, 2026 to May 31, 2026
    v3
  3. Minor Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study sites: 0 to 1
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in C-peptide (ng/mL)
Timeframe: 48-week

Secondary (5)

PK Parameter - Maximum Concentration (Cmax)
PK Parameter - Time to reach maximum concentration (Tmax)
PK Parameter - terminal half-life t1/2
PK Parameter - Area under the curve
Propotion of subjects with change in C-peptide greater than or equal to 0.2 ng/mL

Arms and interventions

OPT101, 1.0mg/kg, 1.5 mg/kg and 2.0 mg/kgExperimental

Part A. 6 subjects will receive 1.0mg/kg OPT101 6 subjects will receive 1.5mg/kg OPT101 6 subjects will receive 2.0mg/kg OPT101

Part B - OPT101 and Placebo to MatchExperimental

The highest tolerated dose from Part A will be tested over 48 weeks. 27 subjects (18 investigational product: 9 placebo)

Part C - OPT101 and Placebo to MatchExperimental

The highest tolerated dose in Part A will be dosed. 27 subjects (18 investigational product, 9 placebo)

Drugs: OPT101

Other: OPT101 Placebo to Match (PTM)

Sites

5 sites in 1 country